All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

TB-500 peptide

TB-500 is a synthetic peptide studied for its potential role in tissue repair, inflammation regulation, and cellular migration. It is related to a naturally occurring protein called thymosin beta-4, which is present in many tissues of the body.

TB-500 peptide is considered a research peptide derived from Thymosin beta-4, a protein involved in processes such as wound healing, cell movement, and tissue regeneration.

Because of its biological activity in experimental models, TB-500 has been studied in research related to muscle recovery, tendon repair, and regenerative biology.

Despite growing interest in this peptide, TB-500 is considered an experimental compound and has not been approved as a pharmaceutical drug by major regulatory authorities.

How TB-500 peptide works

TB-500 peptide is believed to mimic some of the biological effects of thymosin beta-4, a protein involved in cellular repair and cytoskeletal regulation. Experimental research suggests that the peptide may:

  • support cell migration and tissue remodeling

  • influence processes involved in angiogenesis, the formation of new blood vessels

  • regulate actin dynamics, which play an important role in cellular structure and movement

  • modulate certain inflammatory responses

These mechanisms are important in biological processes such as wound healing and tissue regeneration, which is why thymosin beta-4 and related peptides have been studied in regenerative medicine research.

However, the exact biological mechanisms of TB-500 in humans remain incompletely understood.

Clinical trials and evidence

Most of the scientific research on TB-500 peptide has been conducted in laboratory and animal studies examining the biological activity of thymosin beta-4. Research has explored potential roles in:

  • muscle and tendon injury models

  • experimental studies of wound healing

  • investigations of tissue regeneration and cellular repair mechanisms

Some experimental findings suggest that thymosin beta-4–related peptides may influence biological processes involved in tissue repair.

However, TB-500 itself has not undergone extensive clinical trials in humans, and most available information comes from preclinical research rather than controlled clinical studies.

Because of this, its clinical effectiveness and safety in humans have not been conclusively established.

Possible side effects of TB-500 peptide:

Because TB-500 peptide is primarily studied in experimental settings, its complete safety profile in humans has not been fully established. Reported or possible side effects may include:

  • headache

  • fatigue

  • mild gastrointestinal discomfort

  • injection site reactions

Further clinical research is required to determine the long-term safety and potential risks associated with this peptide.

TB-500 is considered an experimental peptide studied primarily in regenerative and cellular biology research and is not approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

TB-500 peptide
Action: Tissue regeneration, angiogenesis and cellular migration support | Category: regenerative peptide
Experimental dosage: 2-2,5 mg | Frequency: 2x a week | Timing: morning or evening | Cycle on: 4 weeks — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, unusual tissue or muscle pain, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 8-12 weeks
Effectiveness: ■■■▢▢ | Safety: ■■■▢▢

Related peptides

Peptides from the same functional group:Arg-BPC-157, BPC-157, GHK-Cu, Matrixyl, PTD-DBM, Thymosin β4

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged